贝伐珠单抗治疗子宫内膜癌的新进展

New Progress of Bevacizumab in the Treatment of Endometrial Carcinoma

子宫内膜癌(endometrial carcinoma,EC)是女性生殖系统常见的恶性肿瘤之一,约占女性生殖系统恶性肿瘤的20%~25%,占女性全身恶性肿瘤的8%。在治疗上,子宫内膜癌以外科手术为主,辅以放疗、化疗、内分泌治疗以及生物治疗等。研究表明,子宫内膜癌的疾病的治疗预后与VEGF-D,VEGFR-3,VEGF-3,LYVE-1的表达有直接关系。肿瘤细胞分泌的VEGF生物学活性物质越多,肿瘤的新生血管就越多,进而其侵袭性越强。通过贝伐珠单抗可抑制VEGF生物学活性物质的分泌,是EC临床治疗的新思路。本文对贝伐珠单抗对子宫内膜癌细胞的治疗及其作用机制进行初步阐述。

Endometrial carcinoma(endometrial carcinoma,EC) is one of the common malignant tumors of the female reproductive system, accounting for about 20%-25% of the malignant tumors of the female reproductive system and 8% of the malignant tumors of the female whole body. In the treatment, endometrial cancer is a surgical procedure, supplemented by radiotherapy, chemotherapy, endocrine therapy, and biological treatment. The results indicated that the treatment of endometrial carcinoma was related to the expression of VEGF-D, VEGFR-3, VEGF-3 and LYVE-1. The more the biological active substance of VEGF secreted by the tumor cells, the more the new blood vessels of the tumor, and the more aggressive the tumor. Bevacizumab can inhibit the secretion of biologically active substance of VEGF, and it is a new thought of EC clinical treatment. In this paper, the treatment and mechanism of bevacizumab on endometrial cancer cells are described.